PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in <i>SMARCA4</i> -Mutated Cancers

PRT3789 selectively degrades SMARCA2 and demonstrates activity in SMARCA4-deficient cancers while sparing wild-type models, validating paralog synthetic lethality, and supporting clinical development in SMARCA4-mutated patients, a population with high unmet need.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2025-09-24
DOI
https://doi.org/10.1158/0008-5472.can-25-1141
Citations
5
Primary Topic
Chromatin Remodeling and Cancer
Type
article
Field-Weighted Citation Impact
4.03
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers

Alice Da Silva, Chaofeng Dai, Joseph Rager, Sandy Geeganage et al.
5 citations
Cancer Research
Chromatin Remodeling and Cancer
4.03
article

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers

Alice Da Silva, Chaofeng Dai, Joseph Rager, Sandy Geeganage, Liang Lu, Chris Tankersley, Jennifer Xavier, Ganfeng Cao, Monisha Sivakumar, Peggy Scherle, Carly Bachner, Andrew P. Combs, Koichi Ito, Jessica Burtell, Klare Bersch, Miles Cowart, Anjana Agarwal, Bruce Ruggeri, Kris Vaddi, Stefan Ruepp, Komali Vykuntam, Jack Carter, Neha Bhagwat, William Novotny, Hsin‐Yao Tang, Min Wang, Olusola Peace Osinubi, Jane Huang, Alexander Grego, Catline Nobre, Philip Pitis, Ludovic Bigot, Hong Lin, Andrew Moore, Joy M. Cote, Arpita Mondal, Chaoyi Xu, Michael Hulse, Anthony Reichelderfer, Diane Heiser, CoreyHannah Basch, Sang Hyun Lee, Justin Kurian, Manoel C.P. Soares, J. Park, Bo Shen, Tom Emm, Melissandre Meteau
article en
5 citations

Abstract

PRT3789 selectively degrades SMARCA2 and demonstrates activity in SMARCA4-deficient cancers while sparing wild-type models, validating paralog synthetic lethality, and supporting clinical development in SMARCA4-mutated patients, a population with high unmet need.

Cancer ResearchVol. 86(1)
The Wistar Institute (US), Inserm (FR), Wilmington University (US), Université Paris-Saclay (FR), Institut Gustave Roussy (FR), PreludeDx (United States) (US)
Openalex Percentile: Top 6%
Chromatin Remodeling and Cancer
4.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.